← Back to Search

TraceIT tissue marker injection for Pancreatic Adenocarcinoma

N/A
Waitlist Available
Led By Amol Narang, MD
Research Sponsored by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up day 1
Awards & highlights

Study Summary

This trial is testing whether a new tissue marker can help doctors better target radiation therapy to pancreatic cancer, with the goal of avoiding duodenum toxicity and improving clinical outcomes.

Eligible Conditions
  • Pancreatic Adenocarcinoma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~day 1
This trial's timeline: 3 weeks for screening, Varies for treatment, and day 1 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of Patients Where TraceIT Tissue Marker Placement Achieved

Trial Design

1Treatment groups
Experimental Treatment
Group I: TraceIT tissue marker injectionExperimental Treatment1 Intervention
The TraceIT injection will be performed during the endoscopic fiducial placement which is the standard of care. CTs to serially confirm TraceIT positioning will be performed on the same day during patient visits for their middle (2nd or 3rd fraction) and last (5th fraction) radiation therapy treatments
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
TraceIT tissue marker injection
2018
N/A
~10

Find a Location

Who is running the clinical trial?

Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsLead Sponsor
557 Previous Clinical Trials
32,894 Total Patients Enrolled
Augmenix, Inc.Industry Sponsor
1 Previous Clinical Trials
222 Total Patients Enrolled
Amol Narang, MDPrincipal InvestigatorJohns Hopkins SKCCC
3 Previous Clinical Trials
73 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Radiopaque Hydrogel in Patients Undergoing Radiotherapy for Pancreatic Cancer
2018. "Radiopaque Hydrogel in Patients Undergoing Radiotherapy for Pancreatic Cancer". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03307564.
~1 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top